ErythrocyteMembrane-Wrapped Magnetic NanotherapeuticAgents for Reduction and Removal of Blood Cr(VI)
2020
The
hazard of hexavalent chromium (Cr(VI)) from environmental pollution
and medical implanted metal has been recognized widely. However, removal
of trace amount of Cr(VI) in the blood circumstance faces tremendous
difficulties for that most of Cr(VI) located in erythrocytes, thus
there is almost no literature to report the removal of Cr(VI) in blood.
Herein, a removal strategy, named as reduction–adsorption–separation,
is proposed to realize the removal of Cr(VI) in blood. First, magnetic
core–shell mesoporous nanocomposite is fabricated by using
Fe3O4 nanoparticles as magnetic core and mesoporous
silica (MS) as shell, hyperbranched polyamide (HPA) as mesoporous
channel modifier and ascorbic acid (ASC) as the reductant drug loaded
in the mesoporous channels, which is also denoted as Fe/MS/HPA/ASC.
Then, on the basis of the bionic idea, the erythrocyte membrane (EM)-wrapped
Fe/MS/HPA/ASC to protect ASC from deactivation is obtained and named
as the therapeutic agent (Fe/MS/HPA/ASC@EM). During removal process,
the therapeutic agent can enter in erythrocytes to use ASC to reduce
Cr(VI) to Cr(III) and HPA in mesoporous channels to adsorb Cr(III)
and can then be recollected from blood by magnetic separation. Finally,
an animal model of blood Cr(VI) poisoning is constructed and used
to test the removal ability of Cr(VI) from pig blood in vivo, verifying
the effectiveness of this blood Cr(VI) removal strategy, providing
a possible way to design more efficient and biosafe therapeutic agents
for blood purification.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
60
References
5
Citations
NaN
KQI